US 10,206,910 B2Granted

Apilimod for use in the treatment of renal cancer

AssigneeLAM Therapeutics, Inc.

InventorsNeil Beeharry, Sophia Gayle, Sean Landrette, Paul Beckett, Chris Conrad, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein

Life of this patent

Estimating the term…

Abstract

The present disclosure relates to methods for treating renal cancer with apilimod and related compositions and methods.

Claims15

Dependent claims

A method for treating clear cell renal carcinoma in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of apilimod dimesylate in combination with a vascular endothelial growth factor (VEGF) inhibitor.

Dependencies are inferred from the claim text.

Facts

Application: 15/524,844Filed 6 Nov 2015 · us provisional application
Priority: 7 Nov 2014
Published: US 2017/0333408 A123 Nov 2017
Granted: 19 Feb 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification12 codes

A61K 31/44
Having six-membered rings with one nitrogen as the only ring hetero atom: non condensed pyridines; Hydrogenated derivatives thereof
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 31/506
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: not condensed and containing further heterocyclic rings
A61K 31/5377
1,4-Oxazines, e.g. morpholine: not condensed and containing further heterocyclic rings, e.g. timolol

Family

Application62/077,127Us provisional application · filed 7 Nov 2014
US 2017/0333408 A1Pre-grant publication · published 23 Nov 2017
US 10,206,910 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results